



# LEADING THE DEVELOPMENT OF MODERN MEDICINE

RESVERLOGIX CORP. (TSX:RVX) is a late-stage biotechnology company - world leader in EPIGENETICS - dedicated to safely improving the lives of patients with chronic illnesses & COVID-19

**Apabetalone** - a first-in-class BET-inhibitor, oral therapeutic designed to restore the health of patients suffering from vascular diseases through epigenetics. In February 2020, **apabetalone** was granted Breakthrough Therapy Designation by the FDA for a cardiovascular indication following ground-breaking data from Phase 3 study **BETonMACE**. In April 2021, Health Canada approved a Phase 2 study of **apabetalone** for COVID-19, which is actively recruiting patients.




### APABETALONE - A BET INHIBITOR TO REDUCE MAJOR ADVERSE CARDIAC EVENTS (MACE)






## THE FUTURE OF DRUG DEVELOPMENT



While most people are familiar with the inheritance of genes via DNA from one generation to the next, fewer realize the activity of these genes is determined by **epigenetics**, which literally means "on top of" genetics. DNA contains the code that tells our cells what to do, and this instruction manual is the same in every cell and does not change with time. Epigenetic modifications determine which instructions are read and how often each is executed. Via this mechanism, gene activity may be turned up or down like a dimmer switch, allowing cells to specialize into their numerous roles throughout the body. Epigenetic control over the genetic instructions also underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines, such as apabetalone.

### APABETALONE CLINICAL TRIAL HISTORY



#### **BETonMACE Overview**

BETonMACE, initiated in 2015, included 2,425 patients in 13 countries. The trial was completed in September 2019, and results were presented at the 2019 AHA Scientific Sessions. The addition of apabetalone to standard of care therapy after acute coronary syndrome in patients with T2DM and low HDL cholesterol, showed a strong trend towards a reduction in MACE. Statistical significance was reached in the pre-specified renally-impaired subgroup, with an observed hazard reduction of 50%. The pre-specified secondary endpoint of first hospitalization for congestive heart failure (CHF) was reduced by 41% with apabetalone. When CHF was added to the primary endpoint post hoc, a hazard reduction of 21% was measured. Exciting new findings in the trial revealed potential synergy between apabetalone and two other classes of drugs, SGLT2 inhibitors and DPP4 inhibitors.

### **News Highlights**

**Nov. 3, 2021** - RVX enters into a cooperation agreement with the Supreme Council of the Arab-African Economy which has expressed interest in providing necessary investments to support the entry of apabetalone into the Arab-African Economy.

**Nov. 1, 2021** - RVX announced they are in active discussions with the Kingdom of Morocco's Ministry of Health for possible Phase 2 COVID-19 clinical studies within their hospitals using apabetalone.

June 3, 2021 - Resverlogix and EVERSANA<sup>™</sup> announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved.

Analysts

Roth Capital Partners: Jerry Isaacson, PhD

Van Leeuwenhoeck Research: Marcel Wijma, MSc

Zacks: John Vandermosten, CFA

#### **Financial Profile**

- Shares O/S (MM): ~242.9
- Share Price: \$0.51
- Market Cap (MM): ~\$123.9
- 52 week high/low: \$1.12/\$0.40 Total Cash Raised (MM): ~\$520

Notes: \*As at 01-04-2022 \*All figures in CAD\$